Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera

This article was originally published in The Pink Sheet Daily

Executive Summary

The biopharma released the new name and cited a rough pricing range for multiple sclerosis drug BG-12, which has a late March PDUFA date. But management tapped the brakes a bit on analyst sales estimates, offering a few words of caution.


Related Content

Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera
Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression
Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA
Lemtrada A Game Changer In MS, Genzyme Researchers Say
Biogen Leans On Plegridy To Help Extend The Life Of Avonex
Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road
Discount Price May Position Aubagio For Greater Than Expected Uptake In Multiple Sclerosis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts